Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients

The Journal of Infectious Diseases
C TuralB Clotet

Abstract

Seven AIDS patients who were receiving suppressive therapy for previously diagnosed cytomegalovirus (CMV) retinitis were offered treatment with protease inhibitors (PIs). Secondary prophylaxis for CMV was discontinued after 3 months of therapy with PIs if patients had >150 CD4 cells/mm3 and a human immunodeficiency virus (HIV) load of <200 copies/mL and if they were negative for CMV as determined by qualitative CMV polymerase chain reaction (PCR). Ophthalmologic exams were done periodically. After a median follow-up of 9 months (range, 9-12), no new episodes of CMV retinitis were observed. CD4 cell counts were >150 cells/mm3 in all cases, HIV loads were <200 copies/mL, and results for qualitative CMV PCRs remained negative. These observations suggest that for selected patients with healed CMV retinitis who have immunologic and virologic evidence of a clinical response to potent combination antiretroviral therapy, temporary discontinuation of a chronic anti-CMV suppressive therapy may not result in further retinal necrosis. However, the long-term immunologic benefit of PIs and hence the safety of prolonged withdrawal of anti-CMV therapy is unknown.

Citations

Jul 27, 2001·Current Infectious Disease Reports·Asok Kurup, Francesca J. Torriani
May 23, 2003·Current Infectious Disease Reports·William Lawrence Drew
Mar 17, 2004·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Amparo TamaritDavid Navarro
Mar 5, 2004·Survey of Ophthalmology·Tamara R Vrabec
Jan 5, 2002·American Journal of Ophthalmology·Douglas A JabsLarry D Hubbard
Jan 12, 1999·Disease-a-month : DM·H W HorowitzG P Wormser
Dec 2, 1998·Antiviral Research·M D de JongS A Spector
Jan 6, 2001·Infectious Disease Clinics of North America·W Tantisiriwat, W G Powderly
Dec 19, 2000·International Journal of Antimicrobial Agents·A LombardiM R Gismondo
Nov 24, 1999·International Journal of Antimicrobial Agents·M Jouan, C Katlama
Feb 19, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Daniele LilleriGiuseppe Gerna
Feb 19, 2000·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·W G Nichols, M Boeckh
Dec 12, 2001·HIV Medicine·D Salmon-Ceron
Nov 30, 1999·The New England Journal of Medicine·T R RohrerC Rudin
May 11, 2000·The New England Journal of Medicine·J A Kovacs, H Masur
Apr 20, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J S Currier
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W G Powderly
Mar 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S C JohnsonA Weinberg
Dec 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elizabeth L Cooney
Dec 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juan BerenguerUNKNOWN Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis
Jan 26, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valérie ZellerChristine Katlama
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cristina MussiniUNKNOWN Changes in Opportunistic Prophylaxis (CIOP) Study Group
Sep 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jade GhosnChristine Katlama
Feb 7, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cristina MussiniUNKNOWN International Working Group on Cryptococcosis
Apr 20, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hans H HirschManuel Battegay
Apr 21, 2005·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Constance A BensonUNKNOWN Infectious Diseases Society of America
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose M MiroUNKNOWN GESIDA 04/98 Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.